tabalumab

Home
Ligands
tabalumab

GtoPdb Ligand ID: 8000

Synonyms: LY 2127399 | LY2127399

Comment: Tabalumab is a monoclonal antibody directed against B-cell activating factor (BAFF, TNFSF13B). It was being developed as a treatment for autoimmune diseases [1] and B cell malignancies [2].
Peptide sequence and structural information for this antibody are available from its IMGT/mAb-db record. Peptide sequence BLAST search using the heavy chain variable region of tabalumab provides 100% match to a sequence claimed in patent US7317089 [3], and to the antibody with designation 4A5-3.1.1-B4.

No information available.

No information available.

Summary of Clinical Use
Tabalumab progressed to Phase 3 clinical evaluation in patients with SLE [5] and rheumatoid arthritis, but trials in these conditions were terminated due to an observed lack of efficacy. Click here to link to ClinicalTrials.gov. complete list of tabalumab studies.

Summary of Clinical Use

Tabalumab progressed to Phase 3 clinical evaluation in patients with SLE [5] and rheumatoid arthritis, but trials in these conditions were terminated due to an observed lack of efficacy. Click here to link to ClinicalTrials.gov. complete list of tabalumab studies.

Mechanism Of Action and Pharmacodynamic Effects
BAFF acts as an immunostimulant, and is required for the formation, maintenance and survival of B cells [4], and it is thus important for maintaining normal immunity. Over-production of BAFF is implicated in the aberrant production of antibodies associated with autoimmune conditions such as rheumatoid arthritis and systemic lupus erythmatosis. Tabalumab was predicted to limit the effect of abnormal BAFF secretion, reduce reactive antibody production and thereby improve disease symptoms.

Mechanism Of Action and Pharmacodynamic Effects

BAFF acts as an immunostimulant, and is required for the formation, maintenance and survival of B cells [4], and it is thus important for maintaining normal immunity. Over-production of BAFF is implicated in the aberrant production of antibodies associated with autoimmune conditions such as rheumatoid arthritis and systemic lupus erythmatosis. Tabalumab was predicted to limit the effect of abnormal BAFF secretion, reduce reactive antibody production and thereby improve disease symptoms.